公开(公告)号：US12281125B2

公开(公告)日：2025-04-22

申请号：US17414696

申请日：2019-12-17

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew W. Patterson ,  Silvio Roggo ,  Tea Shavlakadze ,  Patrik Zueger

IPC: C07D498/18 ,  A61K31/436 ,  A61K45/06

Abstract: The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.

公开(公告)号：US20220202787A1

公开(公告)日：2022-06-30

申请号：US17442733

申请日：2020-03-25

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Andrew W. Patterson ,  Tea Shavlakadze

IPC: A61K31/439 ,  A61K45/06 ,  C07D498/18

Abstract: Described herein are compounds of Formula (I) that are inhibitors of mTORC1, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

公开(公告)号：US12091424B2

公开(公告)日：2024-09-17

申请号：US17499433

申请日：2021-10-12

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew William Patterson ,  Silvio Roggo ,  Tea Shavlakadze

IPC: C07D498/18 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/02 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/10 ,  A61P35/00 ,  A61P37/00 ,  C07F9/6561

CPC classification number: C07D498/18 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P19/00 ,  A61P19/02 ,  A61P19/10 ,  A61P25/02 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/10 ,  A61P35/00 ,  A61P37/00 ,  C07F9/6561

Abstract: The disclosure relates to compounds of formula (I)




and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

公开(公告)号：US20220064185A1

公开(公告)日：2022-03-03

申请号：US17414696

申请日：2019-12-17

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew W. Patterson ,  Silvio Roggo ,  Tea Shavlakadze ,  Patrik Zueger

IPC: C07D498/18 ,  A61K45/06 ,  A61K31/436

Abstract: The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.

公开(公告)号：US10800793B2

公开(公告)日：2020-10-13

申请号：US16141856

申请日：2018-09-25

Applicant: NOVARTIS AG

Inventor： Simone Bonazzi ,  Michael Connolly ,  David Jonathan Glass ,  Manuel Mihalic ,  Andrew William Patterson ,  Silvio Roggo ,  Tea Shavlakadze

IPC: C07D498/18 ,  A61P35/00 ,  A61P13/12 ,  A61P1/16 ,  A61P25/16 ,  A61P37/00 ,  A61P9/10 ,  A61P19/10 ,  A61P19/00 ,  A61P29/00 ,  A61P31/10 ,  A61P19/02 ,  A61P25/28 ,  A61P3/10 ,  A61P9/12 ,  A61P11/00 ,  A61P3/04 ,  C07F9/6561 ,  A61P25/02

Abstract: The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.